Alzheimer's drug from Biogen to get speedy U.S. review

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Alzheimer's drug from Biogen to get speedy U.S. review

Biogen (BIIB) Well Positioned After FDA Grants Priority Review - Canaccord Genuity

August 7, 2020 12:27 PM EDT

Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $350.00 price target on Biogen (NASDAQ: BIIB), citing the FDA granting priority review for aducanumab, the ex-adu pipeline, financial flexibility, and valuation.

The analyst stated "Given the freshness of the news,... More